Drug Trial Radar · NCT06871046
Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Feb 20, 2025
Primary completion
Sep 22, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Teikoku Seiyaku Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Clinsearch GmbH; CRM Biometrics GmbH; SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH
- First posted
- Mar 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multi-centric clinical trial to evaluate the safety and efficacy of TK-254RX in patients with contusions. The primary objective of this study is to assess the safety of TK-254RX. Secondly objective is to evaluate the efficacy of contusions and adhesion of TK-254RX.
Conditions
- Contusions
Interventions
Esflurbiprofen Topical System (EFTS)Drug
One EFTS is applied to the injured area over 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recording adverse event and serious adverse eventTime frame: Day 1 to Day 8
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Medical Practice Ebert
Siemensstr, Bonn, Germany
Medical Practice Prof. Predel
Siemensstr, Bonn, Germany
Medical Practice Schaale-Maas
Siemensstr, Bonn, Germany
Medical Practice Pabst
Sportschule Puch, Fürstenfeldbruck, Germany
Medical Practice Gastl
Römerstraße, Gilching, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.